• PsiOxus Achieves $15M BMS Milestone contractpharma
    December 13, 2017
    PsiOxus Therapeutics’ Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved, triggering a $15 million milestone payment from development partner, Bristol-Myers Squibb.
PharmaSources Customer Service